Zoey Becker/LinkedIn
Dec 11, 2025, 12:12
Zoey Becker: CSL Proves Efficacy of Hemophilia B Gene Therapy Hemgenix Holds up After 5 Years
Brian James, Chief Operating Officer at Rondaxe Pharma LLC, shared an article on LinkedIn:
“Are the new gene therapies durable? It’s nice to see a resounding “yes” like this.”
Title: ASH: CSL proves efficacy of hemophilia B gene therapy Hemgenix holds up after 5 years
Authors: Zoey Becker
Read the paper here.
Hemostasis Today: Advancing the Discourse in Thrombosis and Hemostasis.
-
Dec 11, 2025, 16:18Caitlin Raymond’s Commentary on Artificial Intelligence in Transfusion Medicine is Out!
-
Dec 11, 2025, 15:20Giles Platford on Takeda’s 5 Year Deal with WFH for The Humanitarian Aid Program!
-
Dec 11, 2025, 15:05Kristof Vercruysse on ”First in Human” Presented at ASH25
-
Dec 11, 2025, 13:59Jeff Schaffnit Shares Sanofi’s Patient Advocacy Voices Series with Caroline Kruse
-
Dec 11, 2025, 12:50Harlan Krumholz on Half-Life of Evidence and The Need for Real-Time Trials
-
Dec 11, 2025, 12:34Riitta Lassila on LMWH Benefits in COVID19
-
Dec 11, 2025, 12:30A Neutrophil-Mesangial Cell Axis Promotes Glomerular Injury in Lupus Nephritis
-
Dec 11, 2025, 12:27Roula Farah: Discussing Rare Bleeding Disorders in Abu Dhabi
-
Dec 11, 2025, 12:21Amirali Ebrahimpour: Escherichia coli–Related DIC Case Report